What's Happening?
LinusBio and Coralis Health have partnered to streamline autism spectrum disorder (ASD) diagnosis. The collaboration integrates LinusBio's ClearStrand-ASD biomarker test with Coralis Health's virtual care platform, reducing wait times for diagnostic evaluations. Families receive results and referrals within five days, with comprehensive evaluations completed in 90 days. This partnership aims to bridge the gap between initial screening and professional evaluation, addressing lengthy delays in accessing diagnostic support.
AD
Why It's Important?
Early diagnosis and intervention are crucial for improving outcomes in children with ASD. Current waitlists for evaluations can delay access to necessary therapies. By providing a direct pathway from screening to diagnosis, the partnership enhances access to timely interventions, potentially improving developmental outcomes for children. It also reduces the burden on clinicians by standardizing care and leveraging technology to improve service delivery.
What's Next?
The partnership will continue to refine and expand its diagnostic services, potentially setting a new standard for ASD evaluations. Healthcare providers may adopt this model to offer comprehensive diagnostic solutions, reducing referral complexity and wait times. The collaboration could lead to broader implementation of virtual diagnostic services, improving access to care for neurodivergent children and families.
